Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics (YMAB) to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Y-mAbs Therapeutics downgraded to Hold from Buy at Clear Street
- Y-mAbs Therapeutics downgraded to Hold from Buy at JonesResearch
- Palantir reports Q2 beat, Caterpillar posts mixed results: Morning Buzz
- Y-mAbs Therapeutics downgraded to Neutral from Outperform at Wedbush